Medication info

Lobartan Tablet 20/160 Milligrams

Prescription medicationTabletOralExpired
Ingredient · strength
Rosuvastatin Calcium›20.8mg / 1 tabletValsartan›160mg / 1 tablet
Manufacturer / importer
Medika Korea Co., Ltd.
Appearance
Brown oval film-coated tablet
Packaging
30 tablets/PTP [(10 tablets/PTP x 3)]
Approval status
Expired

MFDS item code 202003763 · Approved 2020.05.22

This product's status changed to Expired on 2025.05.22. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of hypertension and heart failure; improvement of dyslipidemia; reduction of atherosclerosis and cardiovascular risk
Who takes it
Adults · Children
Adult dose
This medicine is for use in adults only. The dose of valsartan/rosuvastatin should be individualized for each patient based on the efficacy and tolerability of each component. Valsartan Essential hypertension Take with water during or between meals. If possible, it is recommended that the medicine be taken at the same time each day (e.g., in the morning). Adults: The recommended dose is 80 mg of valsartan orally once daily, regardless of sex or race. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum effect after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg once daily or a diuretic may be administered concomitantly. If further blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg once daily. Older adults (75 years and older): Initiate treatment with 40 mg of this medicine once daily. Patients with renal impairment: Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is needed. Creatinine clearance 10 ∼ 20 mL/min: Initiate treatment with 40 mg of this medicine once daily. Creatinine clearance less than 10 mL/min and patients on dialysis: Do not administer this medicine. Patients with volume depletion: For patients with volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), initiate treatment with 40 mg of this medicine once daily. Patients with hepatic impairment: For patients with mild to moderate hepatic impairment, initiate treatment with 40 mg of this medicine once daily; the dose should not exceed 80 mg once daily. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. Heart failure Adults: The recommended initial dose is 40 mg of this medicine orally twice daily. The dose may be increased to 80 mg or 160 mg per dose. When administered concomitantly with a diuretic, a reduction in the diuretic dose should be considered. The maximum daily dose is 320 mg, given in divided doses. Triple therapy with this medicine, an ACE inhibitor, and a beta-blocker is not recommended. Reduction of the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours of the onset of myocardial infarction. The recommended initial dose is 20 mg of this medicine twice daily. The dose may then be increased over several weeks, as tolerated by the patient, to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider reducing the dose if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytic agents, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. Patients with renal impairment: No dose adjustment is necessary when creatinine clearance is 10 mL/min or higher. However, this medicine should not be administered to patients with creatinine clearance less than 10 mL/min or patients on dialysis, as there is no experience with its use in these patients. Patients with hepatic impairment: For patients with mild to moderate hepatic impairment, the daily dose of this medicine should preferably not exceed 80 mg. If a dose of 80 mg or more per day is administered, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. Rosuvastatin Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or longer based on LDL cholesterol levels, treatment goals, and patient response, and may be increased to a maximum of 20 milligrams once daily. Older adults: No dose adjustment is needed. Patients with renal impairment: No dose adjustment is needed in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering 20mg of this medicine to patients with moderate renal impairment. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients. For patients taking valsartan and rosuvastatin concomitantly, switching to this medicine (a combination product containing the same amounts of each active ingredient) may be considered for convenience of administration.
Child dose
The safety and efficacy of this medicine have not been established in children and adolescents under 18 years of age. The safety and efficacy of this medicine have not been established in children and adolescents under 18 years of age.

Ingredients

Manufacturer
Medika Korea Co., Ltd.

Efficacy & effects

Treatment of hypertension and heart failure; improvement of dyslipidemia; reduction of atherosclerosis and cardiovascular risk

  • Primary hypertension
  • heart failure
  • heart failure intolerant to ACE inhibitors
  • left ventricular dysfunction
  • left ventricular systolic dysfunction
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed hyperlipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • primary dysbetalipoproteinemia
  • coronary artery disease
View approved original text

This medication is used for patients who require concurrent administration of Valsartan and Rosuvastatin. Valsartan is used to reduce the risk of mortality after myocardial infarction, for primary hypertension, and for heart failure (especially in patients intolerant to ACE inhibitors). Rosuvastatin helps manage hypercholesterolemia and dyslipidemia, slows the progression of atherosclerosis, and reduces the risk of cardiovascular diseases. It is particularly effective in reducing the risk of stroke, myocardial infarction, and vascular interventions in middle-aged patients with coronary artery disease risk factors. Therefore, this medication is used for the treatment of patients at high risk of hypertension and cardiovascular diseases.

How to take

Adult dose

This medicine is for use in adults only. The dose of valsartan/rosuvastatin should be individualized for each patient based on the efficacy and tolerability of each component. Valsartan Essential hypertension Take with water during or between meals. If possible, it is recommended that the medicine be taken at the same time each day (e.g., in the morning). Adults: The recommended dose is 80 mg of valsartan orally once daily, regardless of sex or race. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum effect after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg once daily or a diuretic may be administered concomitantly. If further blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg once daily. Older adults (75 years and older): Initiate treatment with 40 mg of this medicine once daily. Patients with renal impairment: Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is needed. Creatinine clearance 10 ∼ 20 mL/min: Initiate treatment with 40 mg of this medicine once daily. Creatinine clearance less than 10 mL/min and patients on dialysis: Do not administer this medicine. Patients with volume depletion: For patients with volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), initiate treatment with 40 mg of this medicine once daily. Patients with hepatic impairment: For patients with mild to moderate hepatic impairment, initiate treatment with 40 mg of this medicine once daily; the dose should not exceed 80 mg once daily. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. Heart failure Adults: The recommended initial dose is 40 mg of this medicine orally twice daily. The dose may be increased to 80 mg or 160 mg per dose. When administered concomitantly with a diuretic, a reduction in the diuretic dose should be considered. The maximum daily dose is 320 mg, given in divided doses. Triple therapy with this medicine, an ACE inhibitor, and a beta-blocker is not recommended. Reduction of the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours of the onset of myocardial infarction. The recommended initial dose is 20 mg of this medicine twice daily. The dose may then be increased over several weeks, as tolerated by the patient, to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider reducing the dose if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytic agents, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. Patients with renal impairment: No dose adjustment is necessary when creatinine clearance is 10 mL/min or higher. However, this medicine should not be administered to patients with creatinine clearance less than 10 mL/min or patients on dialysis, as there is no experience with its use in these patients. Patients with hepatic impairment: For patients with mild to moderate hepatic impairment, the daily dose of this medicine should preferably not exceed 80 mg. If a dose of 80 mg or more per day is administered, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. Rosuvastatin Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or longer based on LDL cholesterol levels, treatment goals, and patient response, and may be increased to a maximum of 20 milligrams once daily. Older adults: No dose adjustment is needed. Patients with renal impairment: No dose adjustment is needed in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering 20mg of this medicine to patients with moderate renal impairment. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients. For patients taking valsartan and rosuvastatin concomitantly, switching to this medicine (a combination product containing the same amounts of each active ingredient) may be considered for convenience of administration.

Child dose

The safety and efficacy of this medicine have not been established in children and adolescents under 18 years of age. The safety and efficacy of this medicine have not been established in children and adolescents under 18 years of age.

Precautions

This medication can cause serious harm to the fetus if taken during pregnancy, especially in the second and third trimesters, so it should be discontinued immediately once pregnancy is confirmed. This medication should not be used in patients with a history of allergic reactions, severe liver or kidney dysfunction, or certain genetic diseases. Elderly patients or those with high potassium levels or poor liver function should take this medication with particular caution, and adjustments should be made to ensure that blood pressure does not drop too low. If symptoms such as muscle pain, muscle weakness, or severe fatigue occur during treatment, consult a physician immediately, and necessary blood tests should be conducted to check for muscle damage. This medication may affect liver function, so routine liver function tests before and during treatment are recommended. When taking this medication with other drugs, effectiveness may vary due to interactions, so it is essential to inform about other medications being taken, particularly when taking potassium-sparing diuretics or certain pain relievers. Pregnant or breastfeeding women are advised not to use this medication, and women planning to become pregnant should use appropriate contraceptive methods. This medication is not indicated for use in children and adolescents, as safety and efficacy have not been established. In cases of overdose, severe hypotension or decreased consciousness may occur, necessitating immediate medical attention; as there is no specific antidote, symptom-based treatment is required. This medication should be kept out of the reach of children and should not be transferred to other containers for safety.

Side effects

dyspepsia, nausea, chest discomfort, dizziness, headache, conjunctival hemorrhage, constipation, asthenia, chest pain, facial edema, peripheral edema, nasopharyngitis, urinary tract infection, contusion, increased serum liver amino transferase (AST, ALT) levels, increased serum creatine phosphokinase, increased serum potassium, elevated gamma-glutamyl transferase, musculoskeletal rigidity, limb pain, sensory disturbance, anxiety, upper respiratory infection, pharyngitis, tonsillitis, spinal stenosis, aphasia, oral bleeding, vomiting, insulin-dependent diabetes mellitus, diabetic complications, leg fracture, spinal fracture, fracture, skin mass, second-degree atrioventricular block, vestibular neuritis, retinal detachment, unspecified skin tumor-like condition, herpes zoster, intervertebral disc herniation, hemoptysis, sputum disorder, bronchitis, sensory disturbances, hoarseness, gastroesophageal reflux, diverticulitis, gastritis, stomatitis, carpal tunnel syndrome, chills, facial flushing, increased blood sugar, elevated triglycerides, neck/shoulder pain, toe fracture, osteomyelitis, skin infection, unspecified dermatitis, localized skin reaction, palpitations, worsening angina, auditory disturbances, overactive bladder, increased serum creatinine, benign prostatic hyperplasia, laceration, edema, headache, dizziness, constipation, abdominal pain, pruritus, rash, urticaria, myalgia, myopathy, rhabdomyolysis, asthenia, polyneuropathy, memory loss, peripheral neuropathy, cough, dyspnea, diarrhea, thrombocytopenia, jaundice, hepatitis, Stevens-Johnson syndrome, eosinophilia with systemic symptoms drug reaction syndrome (DRESS), lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, severe muscle weakness, ocular myasthenia, hypotension, orthostatic dizziness, orthostatic hypotension, renal impairment, hyperkalemia, angioedema, syncope, vascular edema, erythema, itching, serum sickness, vasculitis, interstitial pneumonia, hypoglycemia, shock, loss of consciousness, agranulocytosis, leukopenia, thrombocytopenia, decreased hematocrit, decreased hemoglobin, viral infection, upper respiratory infection, cough, diarrhea, fatigue, rhinitis, sinusitis, abdominal pain, abdominal pain, arthralgia, drowsiness, atrial fibrillation, thirst, loss of appetite, lethargy, increased blood pressure, worsening hypertension, palpitations

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to light and should be stored in a sealed container that blocks light. Additionally, it is important to maintain a room temperature between 1°C and 30°C while storing the medication. This helps preserve its effectiveness over time.

Appearance and packaging

Appearance

Brown oval film-coated tablet

Package unit

30 tablets/PTP [(10 tablets/PTP x 3)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.